Diagnosing mild enteropathy celiac disease: a randomized, controlled clinical study.

Area of Science:

• Gastroenterology
• Immunology
• Dietary Medicine

Background:

• Celiac disease diagnosis relies on Marsh III villous atrophy, but symptoms can precede histologic changes.
• Endomysial antibodies are specific predictors of future villous atrophy.
• Early detection and intervention in potential celiac disease are crucial.

Purpose of the Study:

• To investigate if patients with mild enteropathy (Marsh I-II) and positive endomysial antibodies benefit from a gluten-free diet (GFD).
• To compare the outcomes of GFD in patients with mild enteropathy to those with established celiac disease (Marsh III).

Main Methods:

• 70 adults with positive endomysial antibodies underwent endoscopy and clinical evaluation.
• 23 participants with mild enteropathy (Marsh I-II) were randomized to a gluten-containing diet or GFD.
• Clinical, serologic, and histologic assessments were repeated after one year.

Main Results:

• In the gluten-containing group (Marsh I-II), villous architecture worsened, and symptoms/antibody titers persisted.
• In the GFD group (Marsh I-II), symptoms improved, antibody titers decreased, and inflammation reduced, similar to Marsh III controls.
• All participants opted for a lifelong GFD post-trial.

Conclusions:

• Endomysial antibody positivity, even without atrophy, indicates a spectrum of gluten intolerance.
• Gluten-free diet is beneficial for patients with endomysial antibodies, irrespective of enteropathy severity.
• Diagnostic criteria for celiac disease may need re-evaluation to include early-stage gluten intolerance.